【Move to another page】
Quote
https://ift.tt/2KjFYfU
P-081
Medgirl131:
[[File:Trifolium pratense 04.JPG|thumb|right|200px|[[Red clover]].]]
'''Rimostil''' (developmental code name '''P-081''') is a [[dietary supplement]] and [[extract]] of [[isoflavone]]s from [[red clover]] which was under development by Kazia Therapeutics (formerly Novogen) for the prevention of [[postmenopausal osteoporosis]] and [[cardiovascular disease]] and for the treatment of [[menopausal symptoms]] and [[hyperlipidemia]] but was never approved for medical use.<ref name="AdisInsight">https://ift.tt/2Kk3Ksa name="pmid15989501">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid13680814">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid11449083">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid12851275">Liquid error: wrong number of arguments (1 for 2)</ref> It is enriched with isoflavone [[phytoestrogen]]s such as [[formononetin]], [[biochanin A]], [[daidzein]], and [[genistein]], and is proposed to act as a [[selective estrogen receptor modulator]], with both [[estrogen (medication)|estrogen]]ic and [[antiestrogen]]ic effects in different [[tissue (biology)|tissue]]s.<ref name="pmid13680814" /><ref name="pmid11449083" /><ref name="pmid12851275" /> The extract reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for cardiovascular disorders, hyperlipidemia, and postmenopausal osteoporosis prior to the discontinuation of its development in 2007.<ref name="AdisInsight" />
==See also==
* [[Femarelle]]
* [[Menerba]]
==References==
[[Category:Abandoned drugs]]
[[Category:Botanical drugs]]
[[Category:Dietary supplements]]
[[Category:Herbalism]]
[[Category:Isoflavones]]
[[Category:Phytoestrogens]]
[[Category:Selective estrogen receptor modulators]]
'''Rimostil''' (developmental code name '''P-081''') is a [[dietary supplement]] and [[extract]] of [[isoflavone]]s from [[red clover]] which was under development by Kazia Therapeutics (formerly Novogen) for the prevention of [[postmenopausal osteoporosis]] and [[cardiovascular disease]] and for the treatment of [[menopausal symptoms]] and [[hyperlipidemia]] but was never approved for medical use.<ref name="AdisInsight">https://ift.tt/2Kk3Ksa name="pmid15989501">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid13680814">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid11449083">Liquid error: wrong number of arguments (1 for 2)</ref><ref name="pmid12851275">Liquid error: wrong number of arguments (1 for 2)</ref> It is enriched with isoflavone [[phytoestrogen]]s such as [[formononetin]], [[biochanin A]], [[daidzein]], and [[genistein]], and is proposed to act as a [[selective estrogen receptor modulator]], with both [[estrogen (medication)|estrogen]]ic and [[antiestrogen]]ic effects in different [[tissue (biology)|tissue]]s.<ref name="pmid13680814" /><ref name="pmid11449083" /><ref name="pmid12851275" /> The extract reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for cardiovascular disorders, hyperlipidemia, and postmenopausal osteoporosis prior to the discontinuation of its development in 2007.<ref name="AdisInsight" />
==See also==
* [[Femarelle]]
* [[Menerba]]
==References==
[[Category:Abandoned drugs]]
[[Category:Botanical drugs]]
[[Category:Dietary supplements]]
[[Category:Herbalism]]
[[Category:Isoflavones]]
[[Category:Phytoestrogens]]
[[Category:Selective estrogen receptor modulators]]
June 25, 2018 at 09:42PM
